ENLIVEX LTD

ENLVNASDAQ

🏆 #3559 by market capEarnings Sep 4US Equity

$756.90▼ $54.88 (−7.25%)

Simulated price

1h—

24h▼ 7.3%

7d—

14d—

30d—

1y—

🏦Market Cap

$32M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for ENLV.

Trading Snapshot

Day Range: $751.33 – $760.09
52-Week Range: $1.80 – $31.50
Volume: $2.13B
Avg Volume: $2.10B
Shares Outstanding: 16.8M
Next Earnings: Sep 7, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $2M
P/E Ratio: 0.0
P/S Ratio: —
EPS (TTM): $149.76
Dividend Yield: —

Why Investors Own ENLV

✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
✓Healthy economics — 64% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▼ −0.7% YoY

Gross Margin (TTM)

64.1%▲ +2.5% YoY

Operating Income (TTM)

$2M▼ −0.7% YoY

Free Cash Flow (TTM)

$1M▼ −0.7% YoY

About ENLIVEX LTD

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

🦦